SCHEMBL16202044

SCHEMBL16202044

Cc1cc(C)n(-c2ccc(C)c(Cl)c2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.59
ALDH1A1 P00352 3/20 0.59
POLB P06746 1/20 0.49
MAPT P10636 4/20 0.49
TP53 P04637 1/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
FTO Q9C0B1 1/20 0.46
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
ATM Q13315 1/20 0.45
HTT P42858 2/20 0.45
STAT1 P42224 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 1/20 0.44
TSHR P16473 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17887004 0.87 L3MBTL1 (0.65) L3MBTL1ALDH1A1MAPTMEN1KMT2A
SCHEMBL12918498 0.83 ALDH1A1 (0.66) L3MBTL1ALDH1A1POLBMAPTMEN1
SCHEMBL17055469 0.83 L3MBTL1 (0.56) L3MBTL1ALDH1A1POLBMAPTFTO
SCHEMBL18692351 0.83 ALDH1A1 (0.71) L3MBTL1ALDH1A1POLBMAPTMEN1
SCHEMBL7251496 0.83 ALDH1A1 (0.60) L3MBTL1ALDH1A1POLBMAPTMEN1
SCHEMBL4235790 0.83 ALDH1A1 (0.56) L3MBTL1ALDH1A1POLBMAPTMEN1
SCHEMBL29120365 0.80 MAPT (0.67) L3MBTL1ALDH1A1MAPTTP53NPC1
SCHEMBL17885745 0.80 POLB (0.44) L3MBTL1ALDH1A1POLBMAPTTP53
SCHEMBL12770967 0.79 POLB (0.64) L3MBTL1ALDH1A1POLBMAPTTP53
SCHEMBL17055470 0.79 L3MBTL1 (0.60) L3MBTL1ALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160249615-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors BASF SE (DE) 2016-09-01 US disclosed
US-20160145219-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2016-05-26 US disclosed
US-20160145202-A1 Strobilurin Type Compounds for Combating Phytopathogenic Fungi BASF SE (DE) 2016-05-26 US disclosed
US-20160122327-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2016-05-05 US disclosed
US-9271501-B2 Use of strobilurin type compounds for combating phytopathogenic fungi resistant to QO inhibitors BASF SE (DE) 2016-03-01 US disclosed
US-20140323305-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors BASF SE (DE) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122327-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI SNX1, DPM1, SNU13 L3MBTL1 2911/4885ALDH1A1 2106/4885POLB 4052/4885
US-20160145219-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI DPM1, CROCC, SNX1 L3MBTL1 2032/4885ALDH1A1 3309/4885POLB 4251/4885
US-20160145202-A1 Strobilurin Type Compounds for Combating Phytopathogenic Fungi DPM1, CROCC, SNX1 L3MBTL1 2032/4885ALDH1A1 3309/4885POLB 4251/4885
US-20140323305-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors SQOR, COX5B, UQCRB L3MBTL1 2888/4885ALDH1A1 2278/4885POLB 198/4885
US-20160249615-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors SQOR, COX5B, UQCRB L3MBTL1 2888/4885ALDH1A1 2278/4885POLB 198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.